8-K: Concord Acquisition Corp II Faces Delisting from NYSE American After Failed Business Combination

Concord Acquisition Corp II is facing delisting from the NYSE American after failing to complete a business combination within the required timeframe, and will not seek further review of the decision.

Summary

• Concord Acquisition Corp II received a notice from the NYSE American on September 3, 2024, indicating that they would begin delisting the company's securities due to the failure to complete a business combination within 36 months of its IPO.
• The company requested a hearing with the Listings Qualifications Panel on November 7, 2024, to argue for more time to complete a business combination.
• On November 13, 2024, the Panel upheld the decision to delist the company.
• Concord Acquisition Corp II does not intend to appeal the decision to the full Committee for Review.
• The company's Class A common stock, warrants, and units are currently trading on the OTCQX, OTCQB, and OTC Pink markets, respectively, under the symbols CNDA, CNDAW, and CNDAU.
• The warrants are exercisable for one share of Class A Common Stock at a price of $11.50 per share.

Sentiment

Score: 2

Explanation: The document indicates a negative outcome for the company, with delisting from a major exchange and no clear path forward. This is a significant setback for the company and its investors.

Negatives

• The company failed to complete a business combination within the required timeframe, leading to delisting from the NYSE American.
• The company's securities are now trading on the less prestigious OTC markets.

Risks

• The delisting from NYSE American could negatively impact investor confidence and the company's ability to raise capital.
• Trading on the OTC markets may result in lower liquidity and higher volatility for the company's securities.
• The failure to complete a business combination raises questions about the company's future prospects.

Future Outlook

The company does not intend to appeal the delisting decision and will continue trading on the OTC markets. The company does not provide any specific forward-looking statements regarding future business combinations or operations.

Management Comments

• The company does not intend to have the full Committee for Review reconsider the decision of the Panel.

Industry Context

This announcement is relevant to the SPAC (Special Purpose Acquisition Company) industry, where companies are formed to raise capital through an IPO and then acquire an existing business. The failure to complete a business combination within the specified timeframe is a risk inherent in the SPAC structure.

Comparison to Industry Standards

• The delisting of Concord Acquisition Corp II highlights the challenges faced by SPACs in finding suitable acquisition targets within the required timeframe.
• Many SPACs have struggled to complete mergers, leading to liquidations or delistings, which is a common risk in the industry.
• The 36-month timeframe is a standard requirement for SPACs listed on major exchanges, and failure to meet this deadline often results in delisting.

Stakeholder Impact

• Shareholders will likely experience a decrease in the value of their investment due to the delisting and move to the OTC markets.
• The company's reputation may be negatively impacted, potentially affecting future business opportunities.

Next Steps

• The company will continue trading on the OTC markets.
• NYSE American will file a Notification of Removal from Listing on Form 25 with the SEC.

Key Dates

Keywords

delisting, NYSE American, business combination, OTC markets, warrants, common stock, SPAC